Drug intelligence / Profile preview

Avicenna Target 3 program

Development stage: Preclinical
Lead developer: Avicenna Biosciences
Modality: Small Molecules
Administration: Oral

Overview

Avicenna Target 3 program refers to an undisclosed drug discovery project by Avicenna Biosciences aimed at treating B-cell lymphomas and pancreatic cancer. The program utilizes the company's proprietary machine learning and medicinal chemistry platform to identify and optimize small molecule candidates. Currently in the early preclinical stages, the program has reached in vitro validation for B-cell lymphoma and is in the discovery phase for pancreatic cancer. Neither the specific molecular target nor the lead candidate's code name has been publicly released.

Targets

HDAC1 (Histone Deacetylase 1)

Beyond the preview

Go deeper on Avicenna Target 3 program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avicenna Target 3 program.

Explore the full profile